BIOMAT Database Logo BIOMAT Database Logo

Angiotensin converting enzyme inhibition: a new therapeutic modality. 1981

H Gavras, and F Charocopos, and H Brunner, and I Gavras

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013722 Teprotide A synthetic nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is identical to the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and ANGIOTENSIN I and has been proposed as an antihypertensive agent. BPP-9a,Bradykinin-Potentiating Peptide 9a,Nonapeptide-Converting Enzyme Inhibitor,SQ-20881,Bradykinin Potentiating Peptide 9a,Enzyme Inhibitor, Nonapeptide-Converting,Nonapeptide Converting Enzyme Inhibitor,Peptide 9a, Bradykinin-Potentiating

Related Publications

H Gavras, and F Charocopos, and H Brunner, and I Gavras
Inhibition of angiotensin-converting enzyme: therapeutic implications.
October 1982, Israel journal of medical sciences,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter's syndrome.
January 1991, European journal of clinical pharmacology,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin-converting enzyme inhibition: a new medical therapy for hypertension?
March 1978, Journal of the Tennessee Medical Association,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin converting enzyme: substrate inhibition.
January 1989, Peptides,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin-converting enzyme inhibition, angiotensin, and cognition.
January 1992, Journal of cardiovascular pharmacology,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin converting enzyme inhibition and renin inhibition.
April 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin-converting enzyme (ACE) inhibition. Therapeutic option for diabetic hypertensive patients.
January 1990, Drugs,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
[Cough and angiotensin converting enzyme inhibition].
April 1990, Harefuah,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Nephrotoxicity of angiotensin converting enzyme inhibition.
May 1987, Kidney international. Supplement,
H Gavras, and F Charocopos, and H Brunner, and I Gavras
Angiotensin-converting enzyme inhibition: renal aspect.
January 1985, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!